Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: The perindopril protection against recurrent stroke study trial
MetadataShow full item record
There is considerable uncertainty regarding the efficacy of blood pressure-lowering therapy in reducing cardiovascular risk in obese people. In this report we examine the effects of blood pressure lowering according to baseline body mass index (kilograms per meter squared) in the Perindopril Protection Against Recurrent Stroke Study. A total of 6105 participants with cerebrovascular disease were randomized to perindopril-based blood pressure-lowering therapy or placebo. The overall mean difference in systolic/diastolic blood pressure between participants assigned active therapy or placebo was 9/4 mm Hg (SE: 0.5/0.3 mm Hg), with no difference by body mass index quarters (<23.1, 23.1 to 25.3, 25.4 to 27.8, and =27.9 kg/m). A consistent treatment benefit was demonstrated for protection against major vascular events across quarters with the following hazard ratios (95% CIs): 0.80 (0.62 to 1.02), 0.78 (0.61 to 1.01), 0.67 (0.53 to 0.86), 0.69 (0.54 to 0.88), and 0.74 (0.66 to 0.84; P for heterogeneity=0.16). Similar results were apparent for stroke and stroke subtypes (all P for heterogeneity =0.07) or with the standard definitions of overweight and obesity (<25, 25 to 29, and =30 kg/m; all P for heterogeneity =0.28). The absolute effects of treatment were, however, more than twice that in the highest compared with the lowest body mass index quartile. Across increasing quarters of body mass index over 5 years, active therapy prevented 1 major vascular event among every 28, 23, 13, and 13 patients treated. In conclusion, blood pressure-lowering therapy produced comparable risk reductions in vascular disease across the whole range of body mass indices in participants with a history of stroke. However, the greater baseline level of cardiovascular risk in those with higher body mass index meant that these patients obtained the greatest benefit. Copyright © 2010 American Heart Association. All rights reserved.
Showing items related by title, author, creator and subject.
A comparative analysis of risk factors and stroke risk for Asian and non-Asian men: The Asia Pacific Cohort Studies CollaborationHyun, K.; Huxley, Rachel; Arima, H.; Woo, J.; Lam, T.; Ueshima, H.; Fang, X.; Peters, S.; Jee, S.; Giles, G.; Barzi, F.; Woodward, M. (2013)Background: The risk of stroke is high in men among both Asian and non-Asian populations, despite differences in risk factor profiles; whether risk factors act similarly in these populations is unknown. Aim: To study the ...
Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials.Blood Pressure Lowering Treatment Trialists' Collaboration; Ying, A.; Arima, H.; Czernichow, S.; Woodward, M.; Huxley, Rachel; Turnbull, F.; Perkovic, V.; Neal, B. (2015)BACKGROUND: The cardiovascular benefits of blood pressure lowering in obese people compared with people of normal weight might depend on choice of drug. We compared the effects of blood pressure-lowering regimens on ...
Does body mass index impact on the relationship between systolic blood pressure and cardiovascular disease?: Meta-analysis of 419 488 individuals from the Asia pacific cohort studies collaborationTsukinoki, R.; Murakami, Y.; Huxley, Rachel; Ohkubo, T.; Fang, X.; Suh, I.; Ueshima, H.; Lam, T.; Woodward, M. (2012)Background and Purpose-: Elevated blood pressure and excess body mass index (BMI) are established risk factors for cardiovascular disease (CVD) but controversy exists as to whether, and how, they interact. Methods-: The ...